Medidata’s Experience-based AI Earns Top Luminary Rating in Everest Group 2026 Review

Core Insights - Medidata has achieved the highest "Luminary" rating in Everest Group's 2026 Innovation Watch for AI applications in clinical development, being the only provider with a 100% market adoption score for its AI-powered solutions [1][2] Group 1: AI Applications and Impact - Medidata's AI functionality supports 80% of FDA novel drug approvals in 2025, showcasing its significant impact on the clinical trial landscape [1] - The report evaluates various AI applications, including Generative AI for data synthesis, Agentic AI for workflow streamlining, and Advanced AI for digital twins and trial simulations, highlighting Medidata's transition of AI from theory to measurable performance [2] Group 2: Efficiency Gains from AI Integration - Medidata's end-to-end platform incorporates experience-based AI, leading to substantial efficiencies in the clinical trial lifecycle, such as a reduction in enrollment times by up to 37% and shortening data review cycles by up to 80% [3][6] - The company saves 70 hours for every 1,000 terms coded through automated medical coding, demonstrating operational scalability [6] Group 3: Company Overview and Achievements - Medidata has over 25 years of technological innovation, supporting more than 38,000 trials and 12 million patients, and is recognized for its expertise and analytics-powered insights [4] - The company has more than 1 million registered users across approximately 2,300 customers, emphasizing its trust and reliability in the industry [4]